[Long COVID] Prediction, diagnosis and treatment with distinct gut microbial signatures

(From left) Professor Siew NG, Associate Director of the Centre for Gut Microbiota Research; Professor Francis CHAN, Dean of Medicine and Director of the Centre for Gut Microbiota Research; and Professor Martin WONG, Professor from The Jockey Club School of Public Health and Primary Care, at CU Medicine.

CU Medicine have identified for the first time distinct gut microbiome profiles associated with post-acute COVID-19 syndrome, more commonly known as “long COVID”. These distinct gut microbial signatures can be used to predict the risk of developing long COVID and diagnose long COVID in patients with persistent symptoms after the acute infection. This is the world’s first study to demonstrate the gut microbiota as a key determinant of long COVID. Study results have been published in the international journal Gut.

CU Medicine has started a large-scale randomised clinical trial to study the efficacy of SIM01 in preventing and treating long COVID. Professor Martin Chi Sang WONG, Professor from The Jockey Club School of Public Health and Primary Care at CU Medicine, said, “We are currently recruiting recovered COVID-19 patients who have persistent symptoms into a clinical trial that aims to reduce long COVID by modulating their gut microbiota.” This study is supported by the Food and Health Bureau’s Health and Medical Research Fund.

For those who are interested, please register at https://bit.ly/3r5KEgK or send a WhatsApp message “To join the RECOVERY study” to 5641 7082.

Press Release: https://bit.ly/3LWzeUM

Full article on Gut: https://bit.ly/3O4Sn8A